Status:
TERMINATED
Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Collaborating Sponsors:
Institut de Cancérologie de la Loire
Conditions:
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Eligibility:
All Genders
50-80 years
Brief Summary
It is of clinical significance to better characterize the intrinsic defects harbored by mesenchymal stromal cells (MSC) in Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) context, as ...
Detailed Description
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal malignancies that are characterized by ineffective hematopoiesis, progressive bone marrow failure, cytogenetic and molecular abnorma...
Eligibility Criteria
Inclusion
- Patients with diagnosed myelodysplasia or acute myeloid leukemia (study place: ICLN) - Specific to the cases cohort
- Age-matched healthy donors undergoing a cardiovascular surgery - Specific to the control cohort
- Signed written informed consent form
- Patient affiliated to a social security regimen or beneficiary of the same
Exclusion
- Medical history of hematological disorders
- Thrombocytopenia, anemia…
- Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent (art. L.1121-6, L.112-7, L.1211-8, L.1211-9)
- Pregnant or breastfeeding women
- Refusing participation
Key Trial Info
Start Date :
November 17 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 19 2022
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT03233074
Start Date
November 17 2017
End Date
April 19 2022
Last Update
May 6 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Saint-Etienne
Saint-Etienne, France, 42055
2
CHU de Saint-Etienne
Saint-Priest-en-Jarez, France, 42270